Several kalihinol natural products, members of the broader isocyanoterpene family of antimalarial agents, are potent inhibitors of Plasmodium falciparum, the agent of the most severe form of human malaria. Our previous total synthesis of kalihinol B provided a blueprint to generate many analogues within this family, some as complex as the natural product and some much simplified and easier to access. Each analogue was tested for blood-stage antimalarial activity using both drug-sensitive and -resistant P. falciparum strains. Many considerably simpler analogues of the kalihinols retained potent activity, as did a compound with a different decalin scaffold made in only three steps from sclareolide. Finally, one representative compound showed reasonable stability toward microsomal metabolism, suggesting that the isonitrile functional group that is critical for activity is not an inherent liability in these compounds.
T he impact of natural products on the development of modern antimalarial therapy cannot be overstated. 1 The discovery of the alkaloid quinine, one of the WHO Model List of Essential Medicines, inspired the development of several clinically used drugs for malaria prophylaxis and therapy, including mefloquine, the 4-aminoquinolines chloroquine and amodiaquine, and the 8-aminoquinolines primaquine and tafenoquine. More recently, another natural product, artemisinin, and its semisynthetic analogues have been used in combination with other antimalarials as a first line treatment for P. falciparum malaria worldwide. The chemical diversity and potentially novel modes of action of natural products make them ideal targets for the development of new classes of potent antimalarials.
The isocyanoterpenes (ICTs) are a group of sponge-derived polycyclic terpenoids bearing the unusual isonitrile functional group. 2 Among the ICTs that have been evaluated for antimalarial activity, 3−5 kalihinol A (1, Figure 1) shows the most potent activity against chloroquine-resistant FCR-3 Plasmodium falciparum. 5, 6 In an important recent development, Shenvi and co-workers demonstrated that representative ICTs have potent liver-stage antimalarial activity in addition to wellestablished blood-stage potency. 7 Interestingly, many structurally diverse ICTs are potent antiplasmodic agents in vitro; however, most of the potent compounds display a common structural feature: the isonitrile-bearing cyclohexane highlighted in red in 1. Comparison of the structural features of each of the ICT subgroups revealed the kalihinols as superior starting points for potential antimalarial lead compound identification; by contrast, the adociane-and amphilectane-type compounds (e.g., 4−6) are particularly hydrophobic. The discovery of simplified kalihinol analogues that retain antimalarial potency, that are easier to make, and that have improved physicochemical characteristics is one of the goals of our research program.
Our recent synthesis of kalihinol B (2), 8 the THF-containing congener of kalihinol A, provided a blueprint for quick access to simplified analogues and the impetus to make them: kalihinol B was nearly as active as kalihinol A in spite of the significant structural change. The dramatic simplification of both structure and synthesis that would accrue from removal of the complex pendant heterocycles could conceivably lead to attractive candidates for further antimalarial development. 9−12 In this letter, we describe the synthesis and antimalarial activity of several simplified kalihinol analogues and show that the motif highlighted in structure 1 is not an absolute determinant of potency, a conclusion also recently reached by Shenvi and coworkers. 7 We further demonstrate that the key isonitrile functional group might not be as serious a metabolic liability as one might expect.
The synthesis of all simplified kalihinol analogues in which the heterocyclic ring was replaced with an isopropyl appendage, started with the synthesis of enantioenriched (+)-cedrelanol (13, Scheme 1). (−)-Cryptone (9) was obtained in enantioenriched form via a Robinson annulation featuring the catalytic asymmetric Michael addition of isovaleraldehyde to methyl vinyl ketone, using the procedure and catalyst of Gellman, 13 as used by Baran. 14 The remainder of the cedrelanol synthesis exactly paralleled the sequence of steps from our kalihinol B synthesis. 8 Two-stage Piers annulation onto cryptone provided the decalones (11 and 12) as a mixture of cis and trans ring fusions. Nucleophilic methylation of the isomeric mixture provided cedrelanol (13) and its stereoisomer torreyol (14) , which were readily separable. Although lacking stereochemical control at C1, the synthesis of these sesquiterpenoids is particularly direct, delivering each in enantioenriched form in only five steps. Application of Shenvi's isonitrile installation 15 to racemic samples of 13 15 and 14 provided the well-known monoisonitrile (±)-10-isocyano-4cadinene (15) , 16 which has been made several times before but via lengthier sequences, 10, 15, 17, 18 and 16, respectively. The latter is the C10 epimer of 10-isocyano-4-amorphene. 16, 19 Synthetic (+)-cedrelanol was used to generate six different bis-isonitrile analogues (Scheme 2). Epoxidation of the C4−C5 alkene was not as highly stereocontrolled as in our kalihinol B synthesis, and 17 and 18 were formed in about a 1.5:1 ratio. Activation of the tertiary alcohol of each diastereomer was uneventful. However, attempted isocyanation at C10 with concomitant isocyanolysis of the epoxide yielded multiple products in each case, which were fully characterized after fluoride-mediated removal of the silyl ether (from silylation of the opened epoxide by TMSCN). From α-epoxide 17, all products contained the C5-isonitrile, as expected on the basis of the Furst−Plattner ring-opening. In this case, invertive displacement of the tertiary trifluoroacetate ester was far from smooth; both stereoisomeric products 19 and 20 were isolated, along with 21, which derived from the competing elimination of the axial tertiary trifluoroacetate ester. Similar problems were observed in our kalihinol B synthesis. 8 With β-epoxide 18, the same general trend was observed, with a somewhat improved production of bis-isonitrile diastereomers 25 and 26, which were formed as C4-isonitrile regioisomers on account of Furst− Plattner ring-opening. Elimination products (27) were also observed.
We believed that significant changes to the C7-appendage (cf. kalihinol A vs B) would have little effect on antimalarial potency. We therefore aimed to access kalihinol-based chemical probe molecules featuring functional handles attached at C7 for mechanism of action studies. The latter stages of a synthesis of analogues with a free primary hydroxyl group are shown in Scheme 3. Appropriate groups can easily be appended by esterification or by conversion of the hydroxyl group to an azide and the use of alkyne/azide cycloaddition methods. The synthesis proved straightforward starting from 4-(tertbutyldimethylsilyloxy)butanal. 20 Robinson annulation (in the racemic manifold), Piers annulation, and nucleophilic methylation afforded decalin 31 (steps are not shown, but are similar to those in Scheme 1 20 ). Epoxidation afforded a ca. 2.5:1 mixture of diastereomers 32 and 33, and application of the 2fold isonitrile introduction to the major diastereomer provided β-hydroxyisonitrile isomers 36 and 37, in low yields over the three-step sequences. In accord with the Furst−Plattner principle, diisocyanide 34 resulted from nucleophilic epoxide opening at C5 to give the C4/C5 diaxial product and invertive displacement of the C10 trifluoroacetate to afford the equatorial isonitrile. However, competitive nucleophilic epoxide opening at C4, possibly a result of chelation of the Lewis acid to the epoxide and the pendant silyl ether, afforded the C4/C5 diequatorial product 35. While some kalihinane natural products with equatorial C4-tertiary hydroxyl group and C5isonitrile are known (the "isokalihinol" series 21 ), we were surprised to observe this product because it is likely to arise from the anti-Furst−Plattner ring-opening of the epoxide. 
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Letter Interestingly, this C4/C5 diequatorial product was isolated as a mixture of C10 epimers of which the C10 axial isonitrile was predominant (ca. 4.4:1 dr). This result was also unexpected because the C10 equatorial isonitrile, resulting from invertive displacement, is normally the major diastereomer under the reaction conditions. Both of these unusual results speak to the subtle and unpredictable reactivities in complex multifunctional settings.
In addition to these planned, simplified analogues, two congeners of kalihinol B were made (Figure 2 ). 20 Monoisonitrile 38 arose (as a mixture of inseparable alkene isomers) from unwanted elimination during attempted C10 isonitrile introduction. C14-nitrile 39 resulted from an attempt to convert a C15-trifluoroacetoxy group into a C15-isonitrile related to 6-hydroxykalihinene (3); hydride shift and cation trapping on the carbon atom of cyanide explains its formation.
Finally, with the goal of accessing ICT-like structures via simple sequences from readily available materials, we produced two isonitrile-bearing compounds from the inexpensive sesquiterpenoid sclareolide (Scheme 4). Superficially, these compounds were meant to reproduce the complex cyclohexane highlighted in 1 (Figure 1) ; however, we note that the different decalin ring fusion forces the isonitrile in sclareolide-derived compounds 43 and 44 to be oriented axially, whereas those in structures 1 through 6 have their isonitriles in an equatorial disposition. This procedure gave rise to two complex ICT analogues in only three steps. 
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All of the compounds synthesized as described above were evaluated for activity against drug-sensitive 3D7 and chloroquine-resistant Dd2 P. falciparum strains (Table 1) . Interestingly, all compounds showed strong antimalarial activity, with IC 50 values ranging from 1.6 nM to ca. 1 μM. Monoisonitrile kalihinol B analogues 38 and 39 retained reasonable potency despite having isonitriles in different positions. 10-Isocyano-4-cadinene (15) , which has been previously tested by Wood, 11, 22 was not as potent as its cisdecalin stereoisomer (16, also epimeric at C10). Most importantly, a variety of kalihinol analogues lacking the complex THP or THF rings of kalihinols A and B, respectively, retained great potency. Analogue 22 10, 22 retains all other structural features of 1 and 2 and is potent. Individually, the change in configuration at the isonitrile-bearing C10 (see 23) or the interchange of C4/C5 substituents (see 28, with the C4isonitrile and C5-secondary alcohol) does not significantly affect potency. The activity of the compounds arising from undesired trifluoroacetate elimination is similar across the board (compare 38, simplified version 24, and 30 with its swapped C4/C5 substituents). The least active compound in the series of C7-isopropyl compounds is 29, with unnatural C10 configuration and C4/C5 substituent interchange. The two chemical probe precursors provided confounding results, wherein analogue (±)-36, with its full set of natural features, proved an order of magnitude less active than (±)-37, in which both the C10 center is inverted, C4 bears an equatorial isonitrile, and C5 bears an equatorial hydroxyl group (note this compound differs in the C4 and C5 configurations relative to 29). Finally, and provocatively, sclareolide-derived bis-isonitrile 43 was the most potent compound synthesized (IC 50 of 1.6 nM against Dd2 strain), with essentially equal potency to kalihinol 
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Letter A, the most potent ICT ever reported (IC 50 of 1.2 nM against FCR-3 strain). Monoisonitrile 44 was significantly less active. Shenvi and colleagues have made closely related compounds to 43 and 44 from dihydrosclareol and reported potent activities. 7 Our findings include: (1) the apparent insignificance of the complex heterocyclic rings in the natural kalihinols; (2) the potential significance of the cis-decalin that is poorly represented among kalihinol natural products previously evaluated for antimalarial activity; (3) the flexibility with respect to axially or equatorially disposed C10 isonitriles; 23 and finally (4) the flexibility with respect to the C4/C5 β-hydroxy isonitrile regiochemistry and configurations in some cases. We note that the motif highlighted in Figure 1 does not seem to be the definitive pharmacophore; unfortunately, it remains difficult to make any clear structure−activity conclusions with the data currently available from natural products and from synthesis work from our laboratories and those carried out previously by others. 5,7−9 Our concerns for the viability of kalihinol compounds as potential preclinical leads hinged in part on the expected in vivo instability of the isonitrile function. Compound (±)-37, one of the chemical probe precursors, retained potency in spite of the serious structural changes relative to the natural kalihinols and in spite of its racemic nature. This compound was subjected to microsomal stability assays, using both human and murine liver microsomes. Interestingly, we found that this potent ICT analogue showed significant stability in the presence of liver microsomes, with half-lives of 142 min (human) and 87 min (murine). 24 While more studies are warranted, this preliminary result suggests that there is nothing intrinsically poor about the salient isonitrile functional groups that are so intimately tied to potency in the ICT family of antimalarials.
The kalihinol scaffold appears to be a promising starting point for the development of interesting antimalarial lead compounds. Many of the simplified analogues synthesized in this study retain high potency and are much easier to access than the natural products; however, the results do not show clear SAR trends. The ICTs have been shown previously to show good selectivity indices 3,5 with respect to mammalian cytotoxicity and to have multistage activity; 7 the latter point conflicts previous notions that their activity is due to inhibition of pathways for heme detoxification. 25 We have now shown that the salient isonitrile functional groups are not a metabolic liability. Future studies aimed to engineer the kalihinane scaffold to identify simpler congeners with improved physicochemical properties and high in vitro and in vivo efficacy are warranted, as are investigations into the incompletely understood mechanism(s) of action of these antimalarial agents.
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